High Dose Conditioning With Ifosfamide, Carboplatin, and Etoposide With Autologous Stem Cell Transplantation for Patients With Recurrent Nasopharyngeal Carcinoma
Phase of Trial: Phase III
Latest Information Update: 25 Jun 2019
Price : $35 *
At a glance
- Drugs Carboplatin (Primary) ; Etoposide phosphate (Primary) ; Ifosfamide (Primary)
- Indications Carcinoma; Nasopharyngeal cancer
- Focus Therapeutic Use
- 29 May 2019 Status changed from completed to discontinued.
- 13 Jun 2017 Status changed from recruiting to completed.
- 07 Aug 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.